SCMOM 2012_NeoStem NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology Go here to see the original: SCMOM 2012_NeoStem - Video … Continue reading →

SCMOM 2012_Stanford Cardiovascular Institute Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford's myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology View post: SCMOM 2012_Stanford Cardiovascular Institute - Video … Continue reading →

SCMOM 2012_Sistemic Sistemic's world leading expertise is on applying microRNA profiling in context with the biology, to areas where there is currently an unmet need for sophisticated tools delivering instructive and robust knowledge of the cell system. From their SistemQC trade; platform they have derived an extensive suite of tools for the cell therapy, gene therapy and bioprocessing community. SistemQC trade;, molecularly characterises cells including stem cells as well as aids in the optimization and monitoring (QC) of the manufacture process. More specifically the initial focus of SistemQC trade; by clients has been on generation of microRNA based ID markers, purity potency assessment and manufacture monitoring optimization. http://www.sistemic.co.uk Presenter: Jim Reid, Chairman and CEO, SistemicFrom:AllianceRegenMedViews:3 1ratingsTime:11:56More inScience Technology Continue reading here: SCMOM 2012_Sistemic - Video … Continue reading →

SCMOM 2012_Regen BioPharma, Inc. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology Visit link: SCMOM 2012_Regen BioPharma, Inc. - Video … Continue reading →

SCMOM 2012_TAP Biosystems TAP Biosystems provides advanced automated systems for cell therapy scale-up and manufacture. At SCMOM 2012 TAP will be showcasing a range of systems including the CellBase CT trade; automated cell culture system for ex vivo expansion of autologous cell therapy products. Plus the Cellmate trade; system for batch production of cells in rollers bottles and the RAFT trade; system for producing biomimetic 3D tissue models in standard plate formats. Staff from TAP will also be available to discuss our collaborative working process to help businesses create new cell therapy scale-up and GMP manufacturing systems. http://www.tapbiosystems.com Presenter: Rosemary Drake, Chief Scientific Officer, TAP BiosystemsFrom:AllianceRegenMedViews:2 0ratingsTime:17:41More inScience Technology View post: SCMOM 2012_TAP Biosystems - Video … Continue reading →

SCMOM 2012_The Clinical Outlook for Regenerative Medicine As many regenerative medicine and cell therapy products move into clinical trials, a clearer understanding of how these products will perform clinically is critical for achieving regulatory approval and ultimately, for commercialization. This session will discuss the major clinical events expected to drive the regenerative medicine sector over the next two years, as well as address some of the key issues facing these products as they approach the marketplace. Moderator: Greg Lucier, MBA, Chairman and CEO, Life Technologies Panelists: Jay Siegel, MD, Chief Biotechnology Officer and Head, Global Pharmaceutical Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson Johnson Paul Simmons, Ph.D., Executive Vice President, Corporate Research and Product Development, Mesoblast Limited Matthias Steger, Ph.D., MBA, Global Head Research and Technology Partnering, Roche Ltd. Dean Tozer, Vice President, Corporate Development, Shire Regenerative MedicineFrom:AllianceRegenMedViews:5 1ratingsTime:01:16:22More inScience Technology Read more: SCMOM 2012_The Clinical Outlook for Regenerative Medicine - Video … Continue reading →